Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs899127658
rs899127658
F2
0.100 GeneticVariation BEFREE Venous thromboembolism at a young age in a brother and sister with coinheritance of homozygous 20210A/A prothrombin mutation and heterozygous 1691G/A factor V Leiden mutation. 10456622

1999

dbSNP: rs1799963
rs1799963
F2
0.730 GeneticVariation BEFREE Apart from F5 rs6025, ABO rs8176719, rs2519093 and F2 rs1799963, additional common and high VTE-risk SNPs among whites are unlikely. 22672568

2012

dbSNP: rs552953108
rs552953108
F2
0.060 GeneticVariation BEFREE Because both factor V R506Q</span> and the HR2 haplotype are very frequent, the effect of their coinheritance on the risk of venous thromboembolism might represent a clinically relevant issue, and screening for HR2 in carriers of factor V R506Q should be considered. 10556190

1999

dbSNP: rs899127658
rs899127658
F2
0.100 GeneticVariation BEFREE Coagulation factor II G20210A and coagulation factor V (Leiden) G1691A single nucleotide polymorphisms (SNPs) are major inherited risk factors of venous thromboembolism. 22744422

2012

dbSNP: rs899127658
rs899127658
F2
0.100 GeneticVariation BEFREE Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations are considered risk factors for venous thromboembolism. 15886665

2005

dbSNP: rs899127658
rs899127658
F2
0.100 GeneticVariation BEFREE Factor V G1691A (FV-Leiden) and prothrombin (PRT) G20210A single nucleotide polymorphisms (SNPs) are major inherited risk factors of venous thromboembolism. 16261289

2005

dbSNP: rs1188383936
rs1188383936
F2
0.100 GeneticVariation BEFREE Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations are considered risk factors for venous thromboembolism. 15886665

2005

dbSNP: rs899127658
rs899127658
F2
0.100 GeneticVariation BEFREE Factor V Leiden (Factor V G1691A), prothrombin gene mutation G20210A, and homozygous C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene are known to predispose venous thromboembolism (VTE). 19520679

2010

dbSNP: rs1188383936
rs1188383936
F2
0.100 GeneticVariation BEFREE Factor V Leiden (Factor V G1691A), prothrombin gene mutation G20210A, and homozygous C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene are known to predispose venous thromboembolism (VTE). 19520679

2010

dbSNP: rs1799963
rs1799963
F2
0.730 GeneticVariation BEFREE Factor V Leiden (FVL or rs6025) and prothrombin gene G20210A (PT or rs1799963) are the genetic variants currently tested for VTE risk assessment. 25341889

2014

dbSNP: rs899127658
rs899127658
F2
0.100 GeneticVariation BEFREE Factor V leiden G1691A/R506Q (FVL), prothrombin G20210A (FII) and methylenetetrahydrofolate reductase (MTHFR) C677T are related genetic risk factors for venous thromboembolism. 22528331

2012

dbSNP: rs552953108
rs552953108
F2
0.060 GeneticVariation BEFREE Factor V leiden G1691A/R506Q (FVL), prothrombin G20210A (FII) and methylenetetrahydrofolate reductase (MTHFR) C677T are related genetic risk factors for venous thromboembolism. 22528331

2012

dbSNP: rs1188383936
rs1188383936
F2
0.100 GeneticVariation BEFREE Factor V leiden G1691A/R506Q (FVL), prothrombin G20210A (FII) and methylenetetrahydrofolate reductase (MTHFR) C677T are related genetic risk factors for venous thromboembolism. 22528331

2012

dbSNP: rs1188383936
rs1188383936
F2
0.100 GeneticVariation BEFREE Factor V Leiden, prothrombin 20210G --> A, methylenetetrahydrofolate reductase 677C --> T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy-related venous thromboembolism. 14597244

2003

dbSNP: rs1188383936
rs1188383936
F2
0.100 GeneticVariation BEFREE Factor V Leiden, PTH G20210A and MTHFR C677T polymorphisms were detected in 40 cancer patients with VTE (group 1) and 40 cancer patients with no evidence of VTE (group 2) by PCR-based DNA analysis. 25565385

2015

dbSNP: rs780225764
rs780225764
F2
0.010 GeneticVariation BEFREE FV A1090G, FV A1299G mutations, and PAI-1 gene polymorphisms may not be a risk factor for VTE in Turkish population. 21078611

2012

dbSNP: rs1799963
rs1799963
F2
A 0.730 GeneticVariation GWASCAT Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor. 28373160

2017

dbSNP: rs3136516
rs3136516
F2
G 0.700 GeneticVariation GWASCAT Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor. 28373160

2017

dbSNP: rs1799963
rs1799963
F2
A 0.730 GeneticVariation GWASCAT Genome-wide association analysis of self-reported events in 6135 individuals and 252 827 controls identifies 8 loci associated with thrombosis. 26908601

2016

dbSNP: rs1799963
rs1799963
F2
A 0.730 GeneticVariation GWASCAT Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. 31676865

2019

dbSNP: rs1799963
rs1799963
F2
0.730 GeneticVariation GWASCAT Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. 31420334

2019

dbSNP: rs3136516
rs3136516
F2
G 0.700 GeneticVariation GWASCAT Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. 31420334

2019

dbSNP: rs1188383936
rs1188383936
F2
0.100 GeneticVariation BEFREE Genotyping for mutations that are possible causes of moderate hyperhomocysteinemia, such as the thermolabile variant (C677T) of methylenetetrahydrofolate reductase (MTHFR), does not seem useful to identify individuals at higher risk for venous thromboembolism. 11011848

2000

dbSNP: rs899127658
rs899127658
F2
0.100 GeneticVariation BEFREE In conclusion, coagulant factor V gene G1691A mutation and protein S deficiency constitute important genetic risk factors in patients with VTE in Eastern Algeria. 26304686

2017

dbSNP: rs552953108
rs552953108
F2
0.060 GeneticVariation BEFREE In non-oral contraceptive users the risk of venous thromboembolism was significantly increased in carriers of R506Q but not in those with the G20210A mutation. 12069454

2002